Skip to content

Ironwood Pharmaceuticals

US · IRWD #3609 by market cap
4.70 -0.01 -0.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 14 in the most recent period (2026/Q3).
  • Total institutional ownership fell 4.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
95.82% -4.36pp
Institutions
275 +14
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.24%
Hedge Fund29.24%
Public Company6.78%
Individual/Insider3.23%
Private Company0.90%
Government Pension Fund0.80%
Bank/Investment Bank0.29%
Family Office/Trust0.25%
Insurance Company0.19%
Other1.07%

Top holders as of 2026-09-30

BlackRock 11.16% · 18.48M sh
Armistice Capital LLC 8.42% · 13.93M sh
Sarissa Capital Management LP 5.55% · 9.19M sh
Renaissance Technologies Corp. 4.86% · 8.04M sh
State Street Global Advisors 4.06% · 6.72M sh
Vanguard Capital Management, LLC 4.01% · 6.63M sh
AQR Capital Management 3.80% · 6.29M sh
Bank of America Corporation 3.15% · 5.22M sh
Vanguard Portfolio Management, LLC 3.06% · 5.06M sh
Acadian Asset Management LLC 3.05% · 5.05M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 28 buys · 22 sells

NameRoleStake
Thomas McCourt Chief Executive Officer 1.04%
Mark Currie Independent Director 0.41%
Michael Shetzline Former Chief Medical Officer, Senior VP and Head of Research & Drug Development 0.23%
Alexander Denner Independent Director 0.20%
Jon Duane Independent Director 0.15%
Julie McHugh Independent Chairperson 0.15%
Tammi Gaskins Senior Vice President & Chief Commercial Officer 0.14%
Jay Shepard Independent Director 0.14%
Marla Kessler Independent Director 0.14%
John Minardo Chief Legal Officer 0.14%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-15 Tammi Gaskins Senior Vice President & Chief Commercial Officer Intent to Sell (Form 144) -6,666 $4.85
2026-09-23 Michael Shetzline Former Chief Medical Officer, Senior VP and Head of Research & Drug Development Intent to Sell (Form 144) -83,306 $4.53
2026-09-14 Alexander Denner Independent Director Other Acquisition +3,694 --
2026-07-19 Jeffrey Silber Chief Medical Officer, Head of Research & Drug Development Other Acquisition +137,036 --
2026-07-06 Ronald Silver Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Automatic Disposition -127,890 $4.52
2026-06-15 Jay Shepard Independent Director Other Acquisition +63,481 --
2026-06-15 Alexander Denner Independent Director Other Acquisition +67,546 --
2026-06-15 Mark Currie Independent Director Other Acquisition +63,481 --
2026-06-15 Catherine Moukheibir Independent Director Other Acquisition +63,481 --
2026-06-15 Julie McHugh Independent Chairperson Other Acquisition +63,481 --
2026-06-15 Julie McHugh Independent Chairperson Automatic Disposition -21,571 $3.73
2026-06-15 Marla Kessler Independent Director Other Acquisition +63,481 --
2026-06-15 Jon Duane Independent Director Other Acquisition +63,481 --
2026-05-18 Ronald Silver Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Other Acquisition +25,000 --
2026-03-16 Sarissa Capital Management LP -- Open Market Disposition -6,730,800 $3.05–3.31
2026-03-12 Alexander Denner Independent Director Other Acquisition +4,451 --
2026-03-09 Thomas McCourt Chief Executive Officer Other Acquisition +409,836 --
2026-03-09 Michael Shetzline Former Chief Medical Officer, Senior VP and Head of Research & Drug Development Other Acquisition +136,612 --
2026-03-09 Ronald Silver Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Other Acquisition +163,934 --
2026-03-09 John Minardo Chief Legal Officer Other Acquisition +136,612 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.

Ironwood Pharmaceuticals discussion 0 comments

Add a comment